Safety and Tolerability of Lanreotide Autogel/Depot (LAN) in Patients (pts) with Neuroendocrine Tumours (NETs): Pooled Analysis of Clinical Studies

被引：0
|
作者：
Phan, A. T. [1 ]
Wolin, E. M. [2 ]
Fisher, G. A. [3 ]
Ruszniewski, P. [4 ]
Pavel, M. [5 ]
Liyanage, N. [6 ]
Mirakhur, B. [7 ]
Braun, S. [6 ]
Caplin, M. [8 ]
Vinik, A., I [9 ]
机构：
[1] Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA
[2] Montefiore Einstein Ctr Canc Care, Bronx, NY USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Beaujon Hosp, Clichy, France
[5] Charite Univ Med Berlin, Berlin, Germany
[6] Ipsen, Les Ulis, France
[7] Ipsen, Basking Ridge, NJ USA
[8] Royal Free Hosp, London, England
[9] Eastern Virginia Med Sch, Norfolk, VA 23501 USA
来源：
NEUROENDOCRINOLOGY | 2017年 / 105卷
关键词：
lanreotide; safety;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
K17
引用
收藏
页码：206 / 206
页数：1
相关论文
共 50 条
  • [21] Antitumor Effects With Lanreotide Autogel/Depot (LAN) in Patients With Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study
    Caplin, Martyn E.
    Phan, Alexandria T.
    Ruszniewski, Philippe
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 351 - 352
  • [22] ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
    Gomez-Panzani, E.
    Vinik, A.
    Wolin, E.
    Audry, H.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 271 - 271
  • [23] Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [24] Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [25] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Thanh, Truong X. M.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2019, 108 : 157 - 157
  • [26] Efficacy and safety of lanreotide autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumours (NETs): CLARINET FORTE study results
    Pavel, M.
    Cwikla, J. B.
    Lombard-Bohas, C.
    Borbath, I.
    Shah, T.
    Pape, U-F.
    Thanh, X-M. Truong
    Houchard, A.
    Ruszniewski, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S773 - S773
  • [27] Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study
    Hoersch, D.
    Raderer, M.
    Lahner, H.
    Rinke, A.
    Denecke, T.
    Koch, A.
    Raspel, A.
    Naschold, B.
    Houchard, A.
    Pavel, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 238 - 238
  • [28] An Exploratory Patient Centric Analysis of the ELECT Trial: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel/Depot (LAN) Treatment for Patients (pts) with Carcinoid Syndrome (CS)
    Duchateau, L.
    Lescrauwaet, B.
    Blot, K.
    Liyanage, N.
    Ray, D.
    Lowenthal, S. P.
    Braun, S.
    Mirakhur, B.
    NEUROENDOCRINOLOGY, 2017, 105 : 194 - 194
  • [29] Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
    Caplin, Martyn E.
    Ruszniewski, Philippe B.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy R.
    Rindi, Guido
    Langley, Alison
    Blumberg, Joelle
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/ Depot (LAN) for Patients with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: The Prospective, Open-label, International, Phase 2 CLARINET FORTE Study
    Pavel, M.
    Dromain, C.
    Majdi, A.
    Houchard, A.
    NEUROENDOCRINOLOGY, 2017, 105 : 204 - 204
12345